Hoffmann-la Roche Inc.

Other

F. Hoffmann-la Roche Ag

Jean-Marc Plancher

Matthias Heinrich Nettekoven

Sven Taylor

Hans G Richter

Olivier Roche

Uwe Grether

Konrad H Bleicher

Rainer Eugen Martin

Werner Neidhart

Bernd Kuhn

Patrizio Mattei

Sabine Kolczewski

Philippe Pflieger

Wolfgang Haap

Rosa Maria Rodriguez-Sarmiento

Werner Mueller

Hans Hilpert

Georg Jaeschke

Wolfgang Guba

Minmin Yang

Song Feng

Eric Vieira

Holger Kuehne

Antonio Ricci

Daniel Rueher

David Banner

Harald Mauser

Mark Rogers-Evans

Simona Maria Ceccarelli

Alexander Alanine

Thomas Luebbers

Markus Rudolph

Elbert Chin

Eric Mertz

Roland Humm

Peter Mohr

Henner Knust

Stephan Roever

Luca Claudio Gobbi

Paul Hebeisen

Caterina Bissantz

Shawn David Erickson

Tanja Schulz-Gasch

Robert James Weikert

Gregory Martin Benson

Delphine Gaufreteau

Theodor Stoll

Fionn O'Hara

Michael G Klug

Cornelia Hertel

Barbara Biemans

Susanne Raab

Silvia Gatti Mcarthur

Franz Schuler

Buelent Kocer

Stephen Deems Gabriel

Tadakatsu Takahashi

Zhi Chen

Thorsten Muser

Dagmar Kube

Gisbert Schneider

Jochen Zuegge

Remy Halm

Feng Chi

Rosa Maria Rodriguez Sarmiento

Lothar Lindemann

Christophe Grundschober

Qingjie Ding

Guido Hartmann

Stephen Matthew Lynch

Walter Vifian

Jing Zhang

Jonathan Mark Bentley

Steven Joseph Berthel

Nan Jiang

Valerie Runtz-Schmitt

Qiang Zhang

Timothy James Morley

Sebastien Schmitt

Guy Anthony Kennett

Joseph Anthony Bilotta

Beat Frei

Ruben Alvarez Sanchez

Rubén Alvarez Sánchez

Jacques Mizrahi

Michael John Bickerdike

Sébastien Schmitt

Han Ma

Peter Hartman

Sean Lightowler

Steven Paul Vickers

David Shawn Erickson

Robert J Weikert

Fionn O`hara

Daniel Zimmerli

The present invention provides new arylsulfonamide compounds having the general formula (I) wherein L, R, R, Rand Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Arylsulfonamide derivatives

The present invention is concerned with indolin-2-one derivatives of general formula wherein the substituents are defined in claim The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.

Indolin-2-one derivatives

The present invention is concerned with indolin-2-one derivatives of general formula wherein   The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.

The present invention is concerned with indolin-2-one derivatives of general formula    The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.

The present invention relates to compounds that may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2. Compounds of formula I are representative, where substituents are defined herein: or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof.

Ethynyl derivatives

The present invention relates to compounds of formula I wherein The compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

The invention relates to the use of a compound of formula I wherein

Oxytocin receptor agonists for the treatment of CNS diseases

The present invention relates to compounds that may be used in the treatment or prevention of disorders relating to allosteric modulation of the mGluR4 receptor. Such compounds may be used for the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection. 

The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are LMP7 inhibitors and may be useful in treating associated inflammatory diseases and disorders such as, for example, rheumatoid arthritis, lupus and irritable bowel disease. 

Substituted triazole boronic acid compounds

The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

N-heteroaryl substituted aniline derivatives as HCV-antivirals

The invention relates to a compound of formula (I) wherein Ato Aand Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used, for example, as inhibitors of the cysteine protease cathepsin.

Pyrrolidine derivatives

Growing community of inventors

Hagenthal-le-Bas, France

Jean-Marc Plancher